|
|
| Zeile 5: |
Zeile 5: |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | {{tp|p=32311318|t=ä. SARS-CoV-2 and ''viral sepsis'': observations and hypotheses |pdf=|usr=}}
| |
| − | {{tp|p=32325026|t=2020. Endothelial cell infection and endotheliitis in COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32292590|t=2020. All about COVID-19 in brief |pdf=|usr=}}
| |
| − | {{tp|p=32245083|t=2020. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far |pdf=|usr=}}
| |
| − | {{tp|p=32365466|t=2020. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32331255|t=2020. Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32316618|t=2020. Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options |pdf=|usr=}}
| |
| − | {{tp|p=32310621|t=2020. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |pdf=|usr=}}
| |
| − | {{tp|p=32199864|t=ä. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children |pdf=|usr=}}
| |
| − | {{tp|p=32196995|t=2020. Clinical features in pediatric COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32187887|t=2020. Insight into COVID-2019 for pediatricians |pdf=|usr=}}
| |
| − | {{tp|p=32134205|t=2020. Clinical and CT features in pediatric patients with COVID?19 infection: Different points from adults |pdf=|usr=}}
| |
| − | {{tp|p=32321540|t=2020. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 42: |
Zeile 28: |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32149036|t=2020. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357545|t=2020. Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment |pdf=|usr=}}
| |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32372801|t=2020. (ACE2) Does a cell protein explain covid-19 severity?|pdf=|usr=}}
| |
| − | {{tp|p=32302706|t=2020. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor |pdf=|usr=}}
| |
| − | {{ttp|p=32150576|t=2020. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | | | |
| Zeile 61: |
Zeile 41: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32343510|t=2020. COVID-19: are T lymphocytes simply watching?|pdf=|usr=}}
| |
| − | {{tp|p=32340873|t=ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype |pdf=|usr=}}
| |
| − | {{tp|p=32317217|t=ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype |pdf=|usr=}}
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 94: |
Zeile 71: |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32322398|t=2020. COVID-19 and intracerebral haemorrhage: causative or coincidental?|pdf=|usr=}}
| |
| − | {{tp|p=32175797|t=2020. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals |pdf=|usr=}}
| |
| − | {{tp|p=32289466|t=2020. The evidence of SARS-CoV-2 infection on ocular surface |pdf=|usr=}}
| |
| − | {{tp|p=32359840|t=ä. Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32359841|t=ä. A Rashomon Moment? Ocular Involvement and COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| Zeile 113: |
Zeile 84: |
| | | | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32216698|t=2020. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility |pdf=|usr=}}
| |
| − | {{tp|p=32297540|t=2020. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32348339|t=2020. Correlation between Heart fatty acid binding protein and severe COVID-19: A case-control study |pdf=|usr=}}
| |
| − | {{tp|p=32298273|t=2020. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 131: |
Zeile 98: |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32259853|t=2020. Nuklearmedizin zu Zeiten der SARS-CoV-2 Pandemie: 18F-FDG-PET/CT zur Visualisierung von COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32358678|t=ä. Computed tomography of the lungs in novel corona virus (COVID-19) infection |pdf=|usr=}}
| |
| − | {{tp|p=32350545|t=ä. Chest computed tomography in children with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32162081|t=ä. Chest computed tomography in children with COVID-19 respiratory infection |pdf=|usr=}}
| |
| − | {{tp|p=32191764|t=2020. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| − | {{tp|p=32347512|t=2020. Group Testing for SARS-CoV-2: Forward to the Past?|pdf=|usr=}}
| |
| − | {{ttp|p=32304912|t=ä. Optical techniques for fast screening towards prevention of the coronavirus COVID-19 outbreak |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32372822|t=2020. Why are ethnic minorities worse affected?|pdf=|usr=}}
| |
| − | {{tp|p=32372818|t=2020. Men hit harder by covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372803|t=2020. Children and covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32243722|t=2020. Lessons unfolding from pediatric cases of COVID?19 disease caused by SARS?CoV?2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32304747|t=2020. Angiotensin receptor blockers and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32360482|t=2020. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?|pdf=|usr=}}
| |
| − | {{tp|p=32298273|t=2020. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study |pdf=|usr=}}
| |
| − | {{tp|p=32343745|t=2020. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 176: |
Zeile 126: |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32322402|t=2020. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355564|t=2020. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32322397|t=2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance |pdf=|usr=}}
| |
| − | {{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372835|t=2020. Trials of BCG vaccine will test for covid-19 protection |pdf=|usr=}}
| |
| − | {{tp|p=32287799|t=2020. Drug trials under way |pdf=|usr=}}
| |
| − | {{tp|p=32353120|t=ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?|pdf=|usr=}}
| |
| − | {{tp|p=32242236|t=ä. COVID-19 and Smoking |pdf=|usr=}}
| |
| − | {{tp|p=32194995|t=2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |pdf=|usr=}}
| |
| − | {{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}}
| |
| − | {{tp|p=32252338|t=2020. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths |pdf=|usr=}}
| |
| − | {{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}}
| |
| − | {{tp|p=32258351|t=2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses |pdf=|usr=}}
| |
| − | {{tp|p=32258207|t=2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32363212|t=ä. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32292817|t=2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32284951|t=2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options |pdf=|usr=}}
| |
| − | {{tp|p=32214286|t=2020. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use |pdf=|usr=}}
| |
| − | {{tp|p=32098302|t=2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |pdf=|usr=}}
| |
| − | {{tp|p=32357471|t=2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |pdf=|usr=}}
| |
| − | {{tp|p=32333199|t=ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32215760|t=2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |pdf=|usr=}}
| |
| − | {{tp|p=32245264|t=2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses |pdf=|usr=}}
| |
| − | {{tp|p=32290348|t=2020. COVID-19: A Brief Overview of the Discovery Clinical Trial |pdf=|usr=}}
| |
| − | {{tp|p=32371086|t=ä. The pros and cons of traditional Chinese medicines in the treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32145402|t=2020. Traditional Chinese medicine for COVID-19 treatment |pdf=|usr=}}
| |
| − | {{tp|p=32205232|t=2020. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32360585|t=ä. Current targeted therapeutics against COVID-19: based on first-line experience in china |pdf=|usr=}}
| |
| − | {{tp|p=32360584|t=ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 |pdf=|usr=}}
| |
| − | {{tp|p=32360583|t=ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32360581|t=ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management |pdf=|usr=}}
| |
| − | {{tp|p=32360580|t=ä. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway |pdf=|usr=}}
| |
| − | {{tp|p=32251726|t=2020. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good |pdf=|usr=}}
| |
| − | {{tp|p=32251725|t=ä. Reply to ?The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good? |pdf=|usr=}}
| |
| − | {{tp|p=32360484|t=2020. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study |pdf=|usr=}}
| |
| − | {{tp|p=32360480|t=ä. Candidate drugs against SARS-CoV-2 and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32334052|t=2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}}
| |
| − | {{tp|p=32247821|t=2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |pdf=|usr=}}
| |
| − | {{tp|p=32302707|t=ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32283223|t=2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32322486|t=2020. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32369479|t=2020. Antibody-based therapies for COVID-19: Can Europe move faster?|pdf=|usr=}}
| |
| − | {{tp|p=32343686|t=2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 240: |
Zeile 144: |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32292589|t=2020. Preventive strategies used by GI physicians during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32372821|t=2020. Crisis hits end-of-life care |pdf=|usr=}}
| |
| − | {{tp|p=32346357|t=ä. Kommentar: Gefahr der COVID-19-Ansteckung durch Medikamentenvernebelung |pdf=|usr=}}
| |
| − | {{tp|p=C7115349|t=ä. Triagestrategie für COVID-19-Verdachtsfälle bei steigender Patientenzahl |pdf=|usr=}}
| |
| − | {{tp|p=32168202|t=2020. COVID19 ?Nuclear Medicine Departments, be prepared!|pdf=|usr=}}
| |
| − | {{tp|p=32247200|t=2020. Blended learning via distance in pre-registration nursing education: A scoping review |pdf=|usr=}}
| |
| − | {{tp|p=32276799|t=2020. Nutrition support in the time of SARS-CoV-2 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32340020|t=2020. European Association for the Study of Obesity Position Statement on the Global COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=C7155392|t=ä. Recommendations for Metabolic and Bariatric Surgery During the COVID-19 Pandemic from IFSO |pdf=|usr=}}
| |
| − | {{tp|p=32347519|t=ä. Letter to the Editor: Intragastric Balloon Removal During the COVID-19 Pandemic: to Postpone or Not? That Is the Question |pdf=|usr=}}
| |
| − | {{tp|p=32314249|t=ä. Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32297078|t=ä. Internal Hernia in the Times of COVID-19: to Laparoscope or Not to Laparoscope?|pdf=|usr=}}
| |
| − | {{tp|p=32213786|t=ä. Coronavirus Disease 2019 (COVID-19) and Pregnancy: Responding to a Rapidly Evolving Situation |pdf=|usr=}}
| |
| − | {{tp|p=32304512|t=ä. Obstetricians on the Coronavirus Disease 2019 (COVID-19) Front Lines and the Confusing World of Personal Protective Equipment |pdf=|usr=}}
| |
| − | {{tp|p=32352523|t=ä. Protecting healthcare workers from inhaled SARS-CoV-2 virus |pdf=|usr=}}
| |
| − | {{tp|p=32304334|t=2020. Taking the Longer View of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32307803|t=2020. Caring for Patients with Advanced Stage Cancer at the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32243668|t=2020. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group |pdf=|usr=}}
| |
| − | {{tp|p=32259322|t=2020. Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records |pdf=|usr=}}
| |
| − | {{tp|p=32227551|t=2020. Cancer Research Ethics and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32369669|t=2020. A Neuroendocrine Tumor Specialty Center in New Orleans (NOLANETS) Response to Patient Care During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32328297|t=2020. COVID-19 Pandemic: A New Chapter in the History of Infectious Diseases |pdf=|usr=}}
| |
| − | {{tp|p=32298029|t=2020. How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience |pdf=|usr=}}
| |
| − | {{tp|p=32293690|t=2020. Oncology in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32373705|t=2020. Repurposing and reshaping of hospitals during the COVID-19 outbreak in South Korea |pdf=|usr=}}
| |
| − | {{tp|p=32333375|t=2020. Protect Healthcare Workers and Patients from COVID-19: The Experience of Two Tertiary Ophthalmology Care Referral Centers in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32327128|t=2020. Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32348831|t=ä. Oculofacial Plastic Surgery and the COVID-19 Pandemic: Current Reactions and Implications for the Future |pdf=|usr=}}
| |
| − | {{tp|p=32359842|t=ä. Academic Ophthalmology during and after the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=C7142701|t=ä. COVID-19 pandemic & head and neck cancer patients management: The role of virtual multidisciplinary team meetings |pdf=|usr=}}
| |
| − | {{tp|p=32330858|t=ä. Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks |pdf=|usr=}}
| |
| − | {{tp|p=32278111|t=2020. CORONA-steps for tracheotomy in COVID-19 patients: A staff-safe method for airway management |pdf=|usr=}}
| |
| − | {{tp|p=32360315|t=2020. COVID alias challenge to onco-rehabilitation and to viable indications and decisions: Cues from an Italian COVID+ oral cancer patient |pdf=|usr=}}
| |
| − | {{tp|p=32353793|t=2020. Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32353792|t=2020. Safe management of laryngectomized patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32335007|t=ä. Letter to the editor regarding ?corona-steps for tracheotomy in codid-19 patients: a staff-safe method for airway management? |pdf=|usr=}}
| |
| − | {{tp|p=32331964|t=ä. CORONA-steps for tracheotomy in COVID-19 patients: A staff-safe method for airway management |pdf=|usr=}}
| |
| − | {{tp|p=32360317|t=ä. CORONA-steps for tracheotomy in COVID-19 patients: a staff-safe method for airway management |pdf=|usr=}}
| |
| − | {{tp|p=32307326|t=ä. Continuing education in oral cancer during coronavirus disease 2019 (covid-19) outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32345570|t=ä. Head and Neck Cancer Care in the COVID-19 Pandemic: A Brief Update |pdf=|usr=}}
| |
| − | {{tp|p=32305310|t=2020. An oncologist perspective on COVID 19: A mysterious cryptic virus |pdf=|usr=}}
| |
| − | {{tp|p=32305309|t=ä. Strategic plan for management in oral and maxillofacial surgery during COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32291154|t=ä. Social media and telemedicine for oral diagnosis and counselling in the COVID-19 era |pdf=|usr=}}
| |
| − | {{tp|p=32342026|t=2020. Tracheostomy Considerations during the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32346775|t=ä. Osteoporosis in the age of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32297225|t=ä. Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32251203|t=2020. Managing patients with chronic pain during the COVID-19 outbreak: considerations for the rapid introduction of remotely supported (eHealth) pain management services |pdf=|usr=}}
| |
| − | {{tp|p=32259247|t=ä. Pain Management Best Practices from Multispecialty Organizations during the COVID-19 Pandemic and Public Health Crises |pdf=|usr=}}
| |
| − | {{tp|p=32348711|t=ä. Response and role of palliative care during the COVID-19 pandemic: A national telephone survey of hospices in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32353150|t=ä. Our Health is the Public?s Health: Pain Management Leadership in the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32321173|t=ä. Pain Management During the COVID-19 Pandemic in China: Lessons Learned |pdf=|usr=}}
| |
| − | {{tp|p=32290643|t=2020. Experience summary of a COVID-19 designated community hospital and its operation model |pdf=|usr=}}
| |
| − | {{tp|p=32324727|t=2020. Management of the corpse with suspect, probable or confirmed COVID-19 respiratory infection - Italian interim recommendations for personnel potentially exposed to material from corpses, including body fluids, in morgue structures and during autopsy practice |pdf=|usr=}}
| |
| − | {{tp|p=32292181|t=2020. Covid-19 current advice for pathologists |pdf=|usr=}}
| |
| − | {{tp|p=32324728|t=2020. What are the priorities of pathologists activities during COVID-19 emergency?|pdf=|usr=}}
| |
| − | {{tp|p=32324726|t=2020. Biosafety in surgical pathology in the era of SARS-Cov2 pandemia A statement of the Italian Society of Surgical Pathology and Cytology |pdf=|usr=}}
| |
| − | {{tp|p=32328170|t=2020. Isolation protocol for a COVID-2019 patient requiring emergent surgical intervention: case presentation |pdf=|usr=}}
| |
| − | {{tp|p=32288785|t=2020. How to risk-stratify elective surgery during the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32336348|t=2020. Effective health communication ? a key factor in fighting the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32358675|t=ä. Pediatric radiology and the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32333285|t=ä. Consensus recommendations for the care of children receiving chronic dialysis in association with the COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32153742|t=2020. 2019-nCoV: Polite with children!|pdf=|usr=}}
| |
| − | {{tp|p=32343836|t=ä. COVID-19 and the Advancement of Digital Physical Therapist Practice and Telehealth |pdf=|usr=}}
| |
| − | {{tp|p=32302407|t=ä. Impact of COVID-19 on Physical Therapist Practice in Portugal |pdf=|usr=}}
| |
| − | {{tp|p=32302404|t=ä. The Essential Role of Home- and Community-Based Physical Therapists During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32280993|t=ä. Home and Community-Based Physical Therapist Management of Adults With Post?Intensive Care Syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32280973|t=ä. Italian Physical Therapists? Response to the Novel COVID-19 Emergency |pdf=|usr=}}
| |
| − | {{tp|p=32330124|t=2020. Leveraging open hardware to alleviate the burden of COVID-19 on global health systems |pdf=|usr=}}
| |
| − | {{tp|p=32312528|t=ä. Early reflection on the global impact of COVID19, and implications for physiotherapy |pdf=|usr=}}
| |
| − | {{tp|p=32323287|t=2020. Positionspapier zur praktischen Umsetzung der apparativen Differenzialtherapie der akuten respiratorischen Insuffizienz bei COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32289832|t=2020. Empfehlungen zur Durchfuhrung einer Bronchoskopie in Zeiten der COVID-19-Pandemie |pdf=|usr=}}
| |
| − | {{tp|p=32294763|t=2020. Aufgaben der Weaning-Zentren im Pandemiefall COVID-19 |pdf=|usr=}}
| |
| − | ----
| |
| | | | |
| | | | |
| Zeile 328: |
Zeile 159: |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − | {{tp|p=32305069|t=ä. Protecting workers aged 60?69 years from COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32219471|t=ä. Mutterschutz ? auch im Zeitalter der Coronakrise |pdf=|usr=}}
| |
| − | {{tp|p=32354748|t=2020. Working from home in the time of covid-19: how to best preserve occupational health?|pdf=|usr=}}
| |
| − | {{tp|p=32359155|t=ä. COVID-19: opportunity to learn from necessity |pdf=|usr=}}
| |
| − | {{tp|p=32359148|t=ä. COVID-19: a new work-related disease threatening healthcare workers |pdf=|usr=}}
| |
| − | {{tp|p=32107548|t=2020. Occupational risks for COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32347933|t=ä. Covid-19 and Health at Work |pdf=|usr=}}
| |
| − | {{tp|p=32311040|t=2020. COVID-19: Health prevention and control in non-healthcare settings |pdf=|usr=}}
| |
| − | {{tp|p=32239155|t=ä. COVID-19 and experiences of moral injury in front-line key workers |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 350: |
Zeile 171: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=C7102578|t=ä. The SARS-CoV-2 outbreak from a one health perspective |pdf=|usr=}}
| |
| − | {{tp|p=32195311|t=2020. From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ? Call for a One Health approach |pdf=|usr=}}
| |
| − | {{tp|p=32140538|t=2020. The novel Coronavirus (SARS-CoV-2) is a one health issue |pdf=|usr=}}
| |
| − | {{tp|p=32313828|t=2020. A "One-Health" approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32363229|t=ä. The risk of SARS-CoV-2 transmission to pets and other wild and domestic animals strongly mandates a one-health strategy to control the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32065221|t=2019. Coronaviruses: a paradigm of new emerging zoonotic diseases |pdf=|usr=}}
| |
| − | {{tp|p=32325980|t=2020. Systematic Review of Important Viral Diseases in Africa in Light of the One Health Concept |pdf=|usr=}}
| |
| − | {{tp|p=32271768|t=2020. Detection of novel coronaviruses in bats in Myanmar |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32210130|t=2020. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32048560|t=2020. The global spread of 2019-nCoV: a molecular evolutionary analysis |pdf=|usr=}}
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32287797|t=2020. Is it super-spreading?|pdf=|usr=}}
| |
| − | {{tp|p=32287786|t=2020. Coronavirus spreads |pdf=|usr=}}
| |
| − | {{tp|p=32372810|t=2020. How Hubei fought the virus |pdf=|usr=}}
| |
| − | {{tp|p=32292815|t=2020. Base protocol for real time active random surveillance of coronavirus disease (COVID-19) ? Adapting veterinary methodology to public health |pdf=|usr=}}
| |
| − | {{tp|p=32292816|t=2020. Surveillance to improve evidence for community control decisions during the COVID-19 pandemic - Opening the animal epidemic toolbox for public health |pdf=|usr=}}
| |
| − | {{tp|p=32368611|t=2020. COVID-19 and globalization |pdf=|usr=}}
| |
| − | {{tp|p=32346544|t=ä. The Time for Universal Masking of the Public for COVID-19 is Now |pdf=|usr=}}
| |
| − | {{tp|p=32149035|t=2020. Effectiveness for the Response to COVID-19: The MERS Outbreak Containment Procedures |pdf=|usr=}}
| |
| − | {{tp|p=32149043|t=2020. Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts |pdf=|usr=}}
| |
| − | {{tp|p=32257774|t=2020. Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea |pdf=|usr=}}
| |
| − | {{tp|p=32257773|t=2020. Coronavirus Disease-19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea |pdf=|usr=}}
| |
| − | {{tp|p=32257772|t=2020. Cross-Country Comparison of Case Fatality Rates of COVID-19/SARS-COV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32257771|t=2020. KCDC Risk Assessments on the Initial Phase of the COVID-19 Outbreak in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32143502|t=2020. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32362697|t=2020. Accurate closed-form solution of the SIR epidemic model |pdf=|usr=}}
| |
| − | {{tp|p=32343747|t=2020. Estimating the burden of United States workers exposed to infection or disease: A key factor in containing risk of COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32231392|t=2020. Forecasting the novel coronavirus COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32231374|t=2020. Data-based analysis, modelling and forecasting of the COVID-19 outbreak |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| Zeile 406: |
Zeile 197: |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=C7110433|t=ä. Coronaviren: von der banalen Erkältung zum schweren Lungenversagen: Chronologie einer Pandemie |pdf=|usr=}}
| |
| − | {{tp|p=32108160|t=2020. Emergence of a novel human coronavirus threatening human health |pdf=|usr=}}
| |
| − | {{tp|p=31988490|t=2020. Outbreak of a novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32015508|t=2020. A new coronavirus associated with human respiratory disease in China |pdf=|usr=}}
| |
| − | {{tp|p=32015507|t=2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin |pdf=|usr=}}
| |
| − | {{tp|p=32322401|t=2020. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics) |pdf=|usr=}}
| |
| − | {{tp|p=32322400|t=2020. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view |pdf=|usr=}}
| |
| − | {{tp|p=32287808|t=2020. Why the WHO won t use the p-word |pdf=|usr=}}
| |
| − | {{tp|p=32372802|t=2020. How do we leave lockdown?|pdf=|usr=}}
| |
| − | {{tp|p=32359839|t=ä. Symptomatic COVID-19 in Eye Professionals in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32275667|t=2020. Will COVID-19 become the next neglected tropical disease?|pdf=|usr=}}
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32203708|t=ä. COVID-19 outbreak: less stethoscope, more ultrasound |pdf=|usr=}}
| |
| − | {{tp|p=32192583|t=2020. COVID-19: delay, mitigate, and communicate |pdf=|usr=}}
| |
| − | {{tp|p=32344311|t=2020. 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruc?al?ty of Fur?n and relevance w?th cancer |pdf=|usr=}}
| |
| − | {{tp|p=32360951|t=2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?|pdf=|usr=}}
| |
| − | {{tp|p=32368884|t=2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain |pdf=|usr=}}
| |
| − | {{tp|p=C7144332|t=ä. On being human in the face of a pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32372820|t=2020. Can breathing exercises help protect you from covid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32292297|t=ä. Leading on the Edge of Insanity |pdf=|usr=}}
| |
| − | {{tp|p=32346358|t=ä. COVID-19: When Leadership Calls |pdf=|usr=}}
| |
| − | {{tp|p=32313516|t=ä. The Moral Obligation of Nurse Leaders: COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32232545|t=ä. SARS-CoV-2: Herausforderung für alle |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| − | {{tp|p=C7118609|t=ä. NetNCSP: Nonoverlapping closed sequential pattern mining |pdf=|usr=}}
| |
| − | {{tp|p=32365567|t=2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics |pdf=|usr=}}
| |
| − | {{tp|p=32330208|t=2020. Machine learning using intrinsic genomic signatures for rapid classification of novel pathogens: COVID-19 case study |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[PrePrint scene''' | + | *'''[[PrePrint scene''']] |
| | *[https://prelights.biologists.com/ prelights] | | *[https://prelights.biologists.com/ prelights] |
| | | | |
